Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | TEK | Q02763 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719717 | 0.89 | KDR (0.61) | KDRLCKTEKPDGFRBCDK8 | |
| SCHEMBL4717511 | 0.89 | LCK (0.56) | KDRLCKTEKCDK8MAPT | |
| SCHEMBL4714839 | 0.88 | KDR (0.65) | KDRLCKTEKPDGFRB | |
| SCHEMBL4717670 | 0.88 | LCK (0.55) | KDRLCKTEKPDGFRBCDK8 | |
| SCHEMBL4716338 | 0.86 | KDR (0.57) | KDRLCKTEKPDGFRBCDK8 | |
| SCHEMBL4717465 | 0.86 | LCK (0.56) | KDRLCKTEKPDGFRBCDK8 | |
| SCHEMBL4720860 | 0.82 | KDR (0.57) | KDRLCKTEKPDGFRBHTT | |
| SCHEMBL4714699 | 0.82 | MEN1 (0.57) | KDRLCKTEKCDK8HTT | |
| SCHEMBL4035077 | 0.81 | LCK (0.52) | KDRLCKTEKCDK8MEN1 | |
| SCHEMBL4716314 | 0.80 | MAPT (0.57) | LCKTEKMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | KDR 5/4885LCK 391/4885TEK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.